Citations

Showing 10 of 108162 citations.

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies
Siddiqi, Tanya , Frankel, Paul , Kiesel, Brian F. , Christner, Susan M., Ruel, Chris , Song, Joo Y. , Chen, Robert , Kelly, Kevin R. , Kaesberg, Paul, Popplewell, Leslie , Puverel, Sandrine , Forman, Stephen J. , Newman, Edward M. , Song, Joo Y , Puverel, Sandrine , Newman, Edward M , Siddiqi, Tanya , Beumer, Jan Hendrik , Ailawadhi, Sikander , Piekarz, Richard

Mayo Clinic

Leukemia & Lymphoma | October 16, 2019 | Volume: 61 | Issue: 2 | Pages: 309-317

10.1080/10428194.2019.1672052 | PMID 31617432 Get It

In Memoriam: Paul M. Vanhoutte 1940–2019
Webb, R. Clinton , Miller, Virginia

Mayo Clinic

American Journal of Hypertension | October 16, 2019 | Volume: 32 | Issue: 11 | Pages: 1043-1044

10.1093/ajh/hpz144 Get It

Fresh Osteochondral Allograft Transplantation in the Knee: A Viability and Histologic Analysis for Optimizing Graft Viability and Expanding Existing Standard Processed Graft Resources Using a Living Donor Cartilage Program
Denbeigh, Janet M. , Paggi, Carlo Alberto , Galeano‐Garces, Catalina , Bagheri, Leila, Saris, Daniël B.F. , Paradise, Christopher R. , Krych, Aaron J. , Wijnen, André J. van , Paggi, Carlo A, Galeano-Garces, Catalina, van Wijnen, Andre J , Krych, Aaron J , van Wijnen, Andre J , Hevesi, Mario , Larson, A. Noelle , Stuart, Michael J.

Mayo Clinic

CARTILAGE | October 16, 2019 | Volume: 13 | Issue: 1_suppl | Pages: 948S-956S

10.1177/1947603519880330 | PMID 31617404 Get It

Objective This study aims to (1) determine and validate living cartilage allograft transplantation as a novel source for viable osteochondral allograft (OCA) tissues and (2) perform histologic and viability comparisons of living donor cartilage tissues to currently available clinical-grade standard processed grafts. Design Using healthy cartilage from well-preserved contralateral compartments in 27 patients undergoing total knee arthroplasty (TKA) and 10 clinical-grade OCA specimens obtained immediately following operative implantation, standard and living donor OCA quality was evaluated at the time of harvest and following up to 3 weeks of storage on the basis of macroscopic International Cartilage Repair Society grade, histology, and viability. Results Osteochondral samples demonstrated a consistent decrease in viability and histologic quality over the first 3 weeks of storage at 37°C, supporting the utility of an OCA paradigm shift toward early implantation, as was the clinical standard up until recent adoption of transplantation at 14 to 35 days following donor procurement. Samples from the 10 clinical-grade OCAs, implanted at an average of 23 days following graft harvest demonstrated a mean viable cell density of 45.6% at implantation, significantly lower ( P < 0.01) than the 93.6% viability observed in living donor allograft tissues. Conclusions Osteochondral tissue viability and histologic quality progressively decreases with ex vivo storage, even when kept at physiologic temperatures. Currently available clinical OCAs are stored for 2 to 5 weeks prior to implantation and demonstrate inferior viability to that of fresh osteochondral tissues that can be made available through the use of a living donor cartilage program.
Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG
Thorpe, Matthew , Kane, Ari J., Morse, Michael A. , Borges‐Neto, Salvador , Thorpe, Matthew P, Zhu, Jason , Wong, Terence Z.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | October 15, 2019 | Volume: 105 | Issue: 3 | Pages: e494-e501

10.1210/clinem/dgz074 | PMID 31614368 Get It

Abstract Context Prognosis of metastatic pheochromocytoma/paraganglioma following 131-Iodine metaiodobenzylguanidine (MIBG) is incompletely characterized due to small samples and shorter follow-up in these rare, often indolent tumors. Objective To describe long-term survival, frequency, and prognostic impact of imaging, biochemical, and symptomatic response to 131-I MIBG. Design Retrospective chart and imaging review at a tertiary referral center. Patients Six hundred sixty-eight person-years of follow-up in 125 patients with metastatic pheochromocytoma/paraganglioma with progression through prior multimodal treatment. Intervention Median 18 800 MBq 131-I MIBG. Main Outcome Measures Overall survival, Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST) imaging response, symptomatic response per chart review, and biochemical response (20% change over 2 consecutive assays of catecholamines, vanillylmandelic acid, metanephrines, or chromogranin A). Results Median survival standard deviation [SD] from diagnosis was 11.5 years [2.4]; following metastasis, 6.5 years [0.8]; post treatment, 4.3 years [0.7]. Among 88 participants with follow-up imaging, 1% experienced complete response, 33% partial response, 53% stability, and 13% progression. Fifty-one percent showed subsequent progression, median progression-free survival [SD] of 2.0 years [0.6]. Stability/response vs progression at first imaging follow-up (3–6 months) predicted improved survival, 6.3 vs 2.4 years (P = 0.021). Fifty-nine percent of 54 patients demonstrated biochemical response. Fifty percent of these relapsed, with median time to laboratory progression [SD] of 2.8 years [0.7]. Biochemical response did not predict extended survival. Seventy-five percent of 83 patients reported improvement in pretreatment symptoms, consisting primarily of pain (42%), fatigue (27%), and hypertension (14%). Sixty-one percent of these patients experienced subsequent symptomatic progression at median [SD] 1.8 years [0.4]. Symptomatic response did not predict extended survival. Conclusions Imaging, symptomatic, and laboratory response to multimodal treatment including high-dose 131-I MIBG were achieved on long-term follow-up in metastatic pheochromocytoma or paraganglioma. Imaging response at 3 to 6 months was prognostic.
Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel Disease
Neto, Manuel B. Braga , Gregory, Martin , Ramos, Guilherme Piovezani , Bazerbachi, Fateh , Bruining, David H. , Kushnir, Vladimir , Raffals, Laura E. , Ciorba, Matthew A. , Loftus, Edward V. , Deepak, Parakkal , Braga Neto, Manuel B, Ramos, Guilherme P, Abu Dayyeh, Barham K, Bazerbachi, F , Loftus, Edward V , Deepak, Parakkal , Braga Neto, Manuel B , Ramos, Guilherme P , Dayyeh, Barham K. Abu

Mayo Clinic

Inflammatory Bowel Diseases | October 15, 2019 | Volume: 26 | Issue: 7 | Pages: 1089-1097

10.1093/ibd/izz236 | PMID 31613968 Get It

AbstractBackgroundAn association between inflammatory bowel disease (IBD) and obesity has been observed. Little is known about the effect of weight loss on IBD course. Our aim was to determine the impact of bariatric surgery on long-term clinical course of obese patients with IBD, either Crohn's disease (CD) or ulcerative colitis (UC).MethodsPatients with IBD who underwent bariatric surgery subsequent to IBD diagnosis were identified from 2 tertiary IBD centers. Complications after bariatric surgery were recorded. Patients were matched 1:1 for age, sex, IBD subtype, phenotype, and location to patients with IBD who did not undergo bariatric surgery. Controls started follow-up at a time point in their disease similar to the disease duration in the matched case at the time of bariatric surgery. Inflammatory bowel disease medication usage and disease-related complications (need for corticosteroids, hospitalizations, and surgeries) among cases and controls were compared.ResultsForty-seven patients met inclusion criteria. Appropriate matches were found for 25 cases. Median follow-up among cases (after bariatric surgery) and controls was 7.69 and 7.89 years, respectively. Median decrease in body mass index after bariatric surgery was 12.2. Rescue corticosteroid usage and IBD-related surgeries were numerically less common in cases than controls (24% vs 52%; odds ratio [OR], 0.36; 95% confidence interval [CI], 0.08–1.23; 12% vs 28%; OR, 0.2; 95% CI, 0.004–1.79). Two cases and 1 control were able to discontinue biologics during follow-up.ConclusionsInflammatory bowel disease patients with weight loss after bariatric surgery had fewer IBD-related complications compared with matched controls. This observation requires validation in a prospective study design.
Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)
Brown, Justin C. , Zhang, Sui , Ou, Fang‐Shu , Niedzwiecki, Donna , Lenz, Heinz‐Josef , Innocenti, Federico , O’Neil, Bert H. , Polite, Blasé N. , Denlinger, Crystal S. , Atkins, James N., Goldberg, Richard M. , Ng, Kimmie, Blanke, Charles D. , Fuchs, Charles S. , Meyerhardt, Jeffrey A. , Brown, Justin C. , Goldberg, Richard M , Brown, Justin C , Meyerhardt, Jeffrey A , Ou, Fang-Shu , Niedzwiecki, Donna , Venook, Alan P. , Shaw, James Edward , Ng, Kimmie , Mayer, Robert J. , O’Reilly, Eileen M. , Brown, Justin C.

Mayo Clinic

JNCI Cancer Spectrum | October 15, 2019 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/jncics/pkz078 | PMID 32259016 Get It

Abstract Background Diabetes is a prognostic factor for some malignancies, but its association with outcome in patients with advanced or metastatic colorectal cancer (CRC) is less clear. Methods This cohort study was nested within a randomized trial of first-line chemotherapy and bevacizumab and/or cetuximab for advanced or metastatic CRC. Patients were enrolled at 508 community and academic centers throughout the National Clinical Trials Network. The primary exposure was physician-documented diabetes at the time of enrollment. The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS) and adverse events. Tests of statistical significance were two-sided. Results Among 2326 patients, 378 (16.3%) had diabetes. The median follow-up time was 6.0 years. We observed 1973 OS events and 2173 PFS events. The median time to an OS event was 22.7 months among those with diabetes and 27.1 months among those without diabetes (HR = 1.27, 95% CI = 1.13 to 1.44; P &lt; .001). The median time to a PFS event was 9.7 months among those with diabetes and 10.8 months among those without diabetes (HR = 1.16, 95% CI = 1.03 to 1.30; P = .02). Patients with diabetes were more likely to experience no less than grade 3 hypertension (8.1% vs 4.4%; P = .054) but were not more likely to experience other adverse events, including neuropathy. Conclusions Diabetes is associated with an increased risk of mortality and tumor progression in patients with advanced or metastatic CRC. Patients with diabetes tolerate first-line treatment with chemotherapy and monoclonal antibodies similarly to patients without diabetes.
HISTOLOGIC FINDINGS IN VITREORETINAL LYMPHOMA
Albadri, Sam , Pulido, José S. , Macon, William R. , García, Joaquín J. , Salomão, Diva R.

Mayo Clinic

Retina | October 15, 2019 | Volume: 40 | Issue: 2 | Pages: 391-398

10.1097/iae.0000000000002676 | PMID 31972811 Get It

Purpose: We aimed to describe the clinical and histologic findings in a few enucleation cases with intraocular lymphoma. Methods: Retrospective review of pathology files from a 22-year period identified cases with intraocular lymphoma among all enucleation specimens. Patient demographics, clinical findings, laboratory results, radiographic studies, and indication for enucleation were abstracted from electronic health records; slides were reviewed. Results: Four patients (three women and one man; age range, sixth through eighth decades of life) underwent enucleation with a final diagnosis of intraocular lymphoma. Two patients with primary vitreoretinal large B-cell lymphomas had been treated for refractory uveitis. Specimens showed retinal and subretinal infiltrates by atypical large B-lymphocytes and rare neoplastic cells in the vitreous. The remaining two patients had systemic lymphoproliferative disorders. One patient had chronic lymphocytic leukemia and floaters in his eye; vitreoretinal lymphoma developed, consistent with intraocular Richter transformation. The other had diffuse large B-cell lymphoma in remission; however, blurred vision developed, she was treated for panuveitis without improvement, and was later found to have ocular involvement by diffuse large B-cell lymphoma. Conclusion: Our series details the unusual circumstances when an eye is removed for intraocular lymphoma. Different patterns of ocular tissue involvement were observed when we compared primary and secondary lymphomas.
New artificial intelligence system: first validation study versus experienced endoscopists for colorectal polyp detection
Hassan, Cesare , Wallace, Michael B. , Maselli, Roberta , Craviotto, Vincenzo , Spadaccini, Marco , Repici, Alessandro , Spadaccini, Marco , Hassan, Cesare , Wallace, Michael B , Sharma, Prateek

Mayo Clinic

Gut | October 15, 2019 | Volume: 69 | Issue: 5 | Pages: 799-800

10.1136/gutjnl-2019-319914 | PMID 31615835 Get It

Improving Access to Care Through the Establishment of a Local, Teledermatology Network
Costello, Collin M. , Cumsky, Helen J.L., Maly, Connor , Harvey, Jamison A. , Buras, Matthew , Pallagi, Peter J. , Gustaveson, Anna L., Nelson, Steven A. , Pittelkow, Mark R. , Mangold, Aaron R. , Maly, Connor J, Mangold, A R , Buras, Matthew R , Costello, Collin M , Singh, Davinder

Mayo Clinic

Telemedicine and e-Health | October 15, 2019 | Volume: 26 | Issue: 7 | Pages: 935-940

10.1089/tmj.2019.0051 | PMID 31613713 Get It

Innovation in evidence synthesis: A living systematic review of immune checkpoint inhibitors in cancer patients.
Rawal, Samarth, Asghar, Noureen, Akhtar, Maheen, Baral, Chitta , Riaz, Irbaz Bin , Siddiqi, Rabbia , Gajic, Ognjen , Wang, Zhen , Montori, Víctor M. , Herasevich, Vitaly , Go, Ronald S. , Rajkumar, S. Vincent , Murad, M. Hassan

Mayo Clinic

Journal of Global Oncology | October 15, 2019 | Volume: 5 | Issue: suppl | Pages: 80-80

10.1200/jgo.2019.5.suppl.80 Get It

80 Background: Several previous systematic reviews and meta-analyses have attempted to summarize toxicity of Immune Checkpoint inhibitors (ICIs). However, very soon after each one of these reviews has been published, it became outdated. ICIs are currently used in 14 different cancers and data is rapidly evolving from new clinical trials. A living Systematic review, which is defined as a systematic review that is continually updated to incorporate relevant new evidence as it becomes available, is necessary in this situations. Methods: In order to dynamically display content -- including textual data, tables, charts, and graphs – standard data formats and protocols were designed for various components of the systematic reviews carried out by researchers. Given these standardized formats, software was written to interpret this data and output the information in the appropriate format, such as a forest plot or data table. Finally, a dynamic interface that enables user inputs (such as which aspect of the meta-analysis to view) and displays the associated output was designed. The overall living Systematic Review infrastructure includes monthly literature searches, cumulative meta-analysis, and an online reporting platform. Results: We have developed a Living Systematic Review engine that can take in standardized data and reflect this data in an interactive, intuitive manner in the form of text, tables, and plots. This interface can also be manipulated via user input to organize and sort data tables or omit/highlight specific pieces of data. Conclusions: We have initiated the first living systematic review in immune-oncology that will be continuously updated, incorporating relevant new evidence as it becomes available, and will provide accurate and up to date toxicity estimates to support clinical decision making. The Living Systematic Review interface allows users to easily and intuitively access the most recent available clinical evidence on toxicity of ICIs.